Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Kris V Kowdley; Vinay Sundaram; Christie Y Jeon; Kamran Qureshi; Nyan L Latt; Amandeep Sahota; Stephen Lott; Michael P Curry; Naoky Tsai; Nathorn Chaiyakunapruk; Yoori Lee; Jorg Petersen; Peter Buggisch

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Kris V Kowdley
, Vinay Sundaram
, Christie Y Jeon
, Kamran Qureshi
, Nyan L Latt
, Amandeep Sahota
, Stephen Lott
, Michael P Curry
, Naoky Tsai
, Nathorn Chaiyakunapruk
, Yoori Lee
, Jorg Petersen
, Peter Buggisch

Research output: Contribution to journal › Article

Abstract

Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load

CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).

Original language	American English
Journal	Articles, Abstracts, and Reports
State	Published - Apr 1 2017

Access to Document

http://digitalcommons.providence.org/publications/2355

Cite this

Kowdley, K. V., Sundaram, V., Jeon, C. Y., Qureshi, K., Latt, N. L., Sahota, A., Lott, S., Curry, M. P., Tsai, N., Chaiyakunapruk, N., Lee, Y., Petersen, J., & Buggisch, P. (2017). Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Articles, Abstracts, and Reports. http://digitalcommons.providence.org/publications/2355

@article{830b8799e2f241689b9e31b8bd731d33,

title = "Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.",

abstract = "Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).",

author = "Kowdley, \{Kris V\} and Vinay Sundaram and Jeon, \{Christie Y\} and Kamran Qureshi and Latt, \{Nyan L\} and Amandeep Sahota and Stephen Lott and Curry, \{Michael P\} and Naoky Tsai and Nathorn Chaiyakunapruk and Yoori Lee and Jorg Petersen and Peter Buggisch",

year = "2017",

month = apr,

day = "1",

language = "American English",

journal = "Articles, Abstracts, and Reports",

}

TY - JOUR

T1 - Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

AU - Kowdley, Kris V

AU - Sundaram, Vinay

AU - Jeon, Christie Y

AU - Qureshi, Kamran

AU - Latt, Nyan L

AU - Sahota, Amandeep

AU - Lott, Stephen

AU - Curry, Michael P

AU - Tsai, Naoky

AU - Chaiyakunapruk, Nathorn

AU - Lee, Yoori

AU - Petersen, Jorg

AU - Buggisch, Peter

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).

AB - Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).

M3 - Article

JO - Articles, Abstracts, and Reports

JF - Articles, Abstracts, and Reports

ER -

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Abstract

Access to Document

Fingerprint

Cite this